The global transmucosal drug delivery market is expected to grow at a CAGR of 6.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing number of patients suffering from chronic diseases such as diabetes and cancer, which require long-term treatment with drugs that are delivered through transmucosal routes. Transmucosal drug delivery is also preferred for treating acute conditions such as pain and nausea because it provides rapid relief without any side effects. Passive transdermal drug delivery accounted for the largest share in the global transmucosal drug delivery market in 2018, followed by active transdermal drug delivery. Passive transdermal drug delivery is preferred over active transdermal because it does not require any external power source or device for administration and has a lower risk of adverse effects than active transdermal methods. Active transdermal methods are more popular among patients who need immediate relief from pain or nausea but cannot take oral medications due to vomiting or other reasons.
Some Of The Growth Factors Of This Market:
- The increasing prevalence of chronic diseases such as cancer, diabetes, and asthma is driving the growth of the Transmucosal Drug Delivery market.
- Increasing awareness about the benefits of Transmucosal Drug Delivery products among consumers.
- Increasing number of product launches in the Transmucosal Drug Delivery market.
- Growing demand for convenient and easy to use drug delivery systems.
Industry Growth Insights published a new data on “Transmucosal Drug Delivery Market”. The research report is titled “Transmucosal Drug Delivery Market research by Types (Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery), By Applications (Hospital, Clinic, Others), By Players/Companies 3M Pharmaceuticals, Acrux Limited, ALZA Corporation, Antares Pharma, Inc., Apricus BioSciences, Inc, Aveva Drug Delivery Systems, Corium International, Inc, DURECT Corporation, Generex Biotechnology Corporation, Inovio Pharmaceuticals, Inc., Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG), MedPharm LTD, Mylan, Inc., Nemaura Pharma Ltd, Nitto Denko Corporation, Noven Pharmaceuticals, Inc., Pantec Biosolutions AG, Tapemark, tesa Labtec GmbH, TEVA Pharmaceutical Industries Ltd., Zosano Pharma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Transmucosal Drug Delivery Market Research Report
By Type
Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery
By Application
Hospital, Clinic, Others
By Companies
3M Pharmaceuticals, Acrux Limited, ALZA Corporation, Antares Pharma, Inc., Apricus BioSciences, Inc, Aveva Drug Delivery Systems, Corium International, Inc, DURECT Corporation, Generex Biotechnology Corporation, Inovio Pharmaceuticals, Inc., Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG), MedPharm LTD, Mylan, Inc., Nemaura Pharma Ltd, Nitto Denko Corporation, Noven Pharmaceuticals, Inc., Pantec Biosolutions AG, Tapemark, tesa Labtec GmbH, TEVA Pharmaceutical Industries Ltd., Zosano Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Transmucosal Drug Delivery Market Report Segments:
The global Transmucosal Drug Delivery market is segmented on the basis of:
Types
Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- 3M Pharmaceuticals
- Acrux Limited
- ALZA Corporation
- Antares Pharma, Inc.
- Apricus BioSciences, Inc
- Aveva Drug Delivery Systems
- Corium International, Inc
- DURECT Corporation
- Generex Biotechnology Corporation
- Inovio Pharmaceuticals, Inc.
- Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)
- MedPharm LTD
- Mylan, Inc.
- Nemaura Pharma Ltd
- Nitto Denko Corporation
- Noven Pharmaceuticals, Inc.
- Pantec Biosolutions AG
- Tapemark
- tesa Labtec GmbH
- TEVA Pharmaceutical Industries Ltd.
- Zosano Pharma
Highlights of The Transmucosal Drug Delivery Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Passive Transdermal Drug Delivery
- Active Transdermal Drug Delivery
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Transmucosal Drug Delivery Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Transmucosal drug delivery (TMD) is a method of delivering medications through the mucous membranes in the mouth and nose. This delivery method allows for faster absorption into the body than traditional oral or intravenous methods, as well as decreased side effects.
Some of the major companies in the transmucosal drug delivery market are 3M Pharmaceuticals, Acrux Limited, ALZA Corporation, Antares Pharma, Inc., Apricus BioSciences, Inc, Aveva Drug Delivery Systems, Corium International, Inc, DURECT Corporation, Generex Biotechnology Corporation, Inovio Pharmaceuticals, Inc., Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG), MedPharm LTD, Mylan, Inc., Nemaura Pharma Ltd, Nitto Denko Corporation, Noven Pharmaceuticals, Inc., Pantec Biosolutions AG, Tapemark, tesa Labtec GmbH, TEVA Pharmaceutical Industries Ltd., Zosano Pharma.
The transmucosal drug delivery market is expected to register a CAGR of 6.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Transmucosal Drug Delivery Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Transmucosal Drug Delivery Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Transmucosal Drug Delivery Market - Supply Chain
4.5. Global Transmucosal Drug Delivery Market Forecast
4.5.1. Transmucosal Drug Delivery Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Transmucosal Drug Delivery Market Size (000 Units) and Y-o-Y Growth
4.5.3. Transmucosal Drug Delivery Market Absolute $ Opportunity
5. Global Transmucosal Drug Delivery Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Transmucosal Drug Delivery Market Size and Volume Forecast by Type
5.3.1. Passive Transdermal Drug Delivery
5.3.2. Active Transdermal Drug Delivery
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Transmucosal Drug Delivery Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Transmucosal Drug Delivery Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Transmucosal Drug Delivery Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Transmucosal Drug Delivery Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Transmucosal Drug Delivery Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Transmucosal Drug Delivery Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Transmucosal Drug Delivery Demand Share Forecast, 2019-2026
9. North America Transmucosal Drug Delivery Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Transmucosal Drug Delivery Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Transmucosal Drug Delivery Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Transmucosal Drug Delivery Market Size and Volume Forecast by Type
9.7.1. Passive Transdermal Drug Delivery
9.7.2. Active Transdermal Drug Delivery
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Transmucosal Drug Delivery Demand Share Forecast, 2019-2026
10. Latin America Transmucosal Drug Delivery Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Transmucosal Drug Delivery Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Transmucosal Drug Delivery Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Transmucosal Drug Delivery Market Size and Volume Forecast by Type
10.7.1. Passive Transdermal Drug Delivery
10.7.2. Active Transdermal Drug Delivery
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Transmucosal Drug Delivery Demand Share Forecast, 2019-2026
11. Europe Transmucosal Drug Delivery Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Transmucosal Drug Delivery Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Transmucosal Drug Delivery Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Transmucosal Drug Delivery Market Size and Volume Forecast by Type
11.7.1. Passive Transdermal Drug Delivery
11.7.2. Active Transdermal Drug Delivery
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Transmucosal Drug Delivery Demand Share, 2019-2026
12. Asia Pacific Transmucosal Drug Delivery Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Transmucosal Drug Delivery Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Transmucosal Drug Delivery Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Transmucosal Drug Delivery Market Size and Volume Forecast by Type
12.7.1. Passive Transdermal Drug Delivery
12.7.2. Active Transdermal Drug Delivery
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Transmucosal Drug Delivery Demand Share, 2019-2026
13. Middle East & Africa Transmucosal Drug Delivery Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Transmucosal Drug Delivery Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Transmucosal Drug Delivery Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Transmucosal Drug Delivery Market Size and Volume Forecast by Type
13.7.1. Passive Transdermal Drug Delivery
13.7.2. Active Transdermal Drug Delivery
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Transmucosal Drug Delivery Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Transmucosal Drug Delivery Market: Market Share Analysis
14.2. Transmucosal Drug Delivery Distributors and Customers
14.3. Transmucosal Drug Delivery Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. 3M Pharmaceuticals
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Acrux Limited
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. ALZA Corporation
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Antares Pharma, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Apricus BioSciences, Inc
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Aveva Drug Delivery Systems
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Corium International, Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. DURECT Corporation
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Generex Biotechnology Corporation
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Inovio Pharmaceuticals, Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. MedPharm LTD
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Mylan, Inc.
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Nemaura Pharma Ltd
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Nitto Denko Corporation
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Noven Pharmaceuticals, Inc.
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Pantec Biosolutions AG
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Tapemark
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. tesa Labtec GmbH
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. TEVA Pharmaceutical Industries Ltd.
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook